Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Goethe University
Incyte Corporation
Bristol-Myers Squibb
Swiss Cancer Institute
University of California, Davis
Sarcoma Oncology Research Center, LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Eli Lilly and Company
Yale University
City of Hope Medical Center
Mirati Therapeutics Inc.
Case Comprehensive Cancer Center
UNICANCER
Bristol-Myers Squibb
University Hospital, Ghent
Rutgers, The State University of New Jersey
HUYABIO International, LLC.
Mirati Therapeutics Inc.
Tempest Therapeutics
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Nektar Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb
AIO-Studien-gGmbH
Incyte Corporation
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Genocea Biosciences, Inc.
Five Prime Therapeutics, Inc.
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
UNICANCER
University of Michigan Rogel Cancer Center
MedImmune LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Celldex Therapeutics
Bristol-Myers Squibb